Overview

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
JSI-1187-101 phase 1 study
Phase:
PHASE1
Details
Lead Sponsor:
JS InnoPharm, LLC